Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers April 19, 2015
Pharmacy Choice - News - Generic Drugs - April 19, 2015

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 90     Next >>     Go To Page:

4/19/15 - Research and Markets Offers Report: Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab [Professional Services Close - Up]
Research and Markets has announced the addition of the "Competitor Analysis: CD20 Antibodies 2015- Biosimilars and Biosuperiors of Rituximab" report to its offerings. In a release, Research and Markets noted that report highlights include:. The chimeric anti-CD20 antibody rituximab from Biogen Idec and Roche is one of the world's commercially most.
4/19/15 - Research and Markets Offers Report: Competitor Analysis: EGF-R Antibodies 2015 [Professional Services Close - Up]
Research and Markets has announced the addition of the "Competitor Analysis: EGF-R Antibodies 2015- Biosuperiors and Biosimilars of Erbitux" report to its offerings. In a release, Research and Markets noted that report highlights include:. This Competitive Intelligence Report about EGF-R Antibodies 2015- Biosuperiors and Biosimilars of Erbitux prov
4/19/15 - Research and Markets Offers Report: Competitor Analysis: TNF Antibodies 2015 - Biosimilars and Biosuperiors of Humira, Remicade and Enbrel [Professional Services Close - Up]
Research and Markets has announced the addition of the "Competitor Analysis: TNF Antibodies 2015- Biosimilars and Biosuperiors of Humira, Remicade and Enbrel" report to its offerings. In a release, Research and Markets noted that report highlights include:. The five branded anti-TNF antibodies Humira, Remicade, Enbrel, Simponi and Cimzia together a
4/19/15 - United States : Bowditch & Dewey LLP - Teva Pharmaceutical, Actavis among consolidators remaining [TendersInfo (India)]
Mergers and acquisitions among generic pharmaceutical firm has become a norm these days. Mylan has recently announced its plans to acquire Perrigo for $29 billion. A partner at law firm Bowditch& Dewey LLP, Charles Yon, says that Teva Pharmaceutical, Actavis, Forest Laboratories and the U.S. generics business of Abbott Laboratories are the only con
4/18/15 - BRIEF: Mylan says it is not interested in merger with Israeli drug maker [Pittsburgh Post-Gazette]
"Mylan is fully committed to its stand-alone strategy, including its proposal to acquire Perrigo," the company said. Mylan, which earlier this year moved its headquarters to the Netherlands but maintains its base of operations in Cecil, last week revealed it had made an unsolicited, roughly $30 billion bid for the store-brand medication specialist
4/18/15 - SOHM Signs Private Label Contract Manufacturing Agreement for Nutraceutical Products
By a News Reporter-Staff News Editor at Marketing Weekly News SOHM, Inc., a manufacturer of generic Pharmaceutical, Nutraceutical and Cosmeceutical products, announced they have signed private label contract manufacturing for their Nutraceutical units. Shailesh Shah, President and CEO, announced that SOHM India has signed a private label contract
4/17/15 - AMERIGEN Announces Tentative Approval of Generic Bystolic
Pursuant to a 2013 settlement agreement with Forest Laboratories, and subject to FDA final approval of its ANDA, Amerigen may launch its generic product on the date that is the later of three calendar months prior to the expiration of U.S. Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business,
4/17/15 - Bharat Book Bureau: Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion
The leading business intelligence provider, has released its latest research, "Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018- Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion". -The current therapeutic environment in the treatment of RA across the top seven developed markets, including
4/17/15 - COHERUS BIOSCIENCES, INC. FILES (8-K) Disclosing Other Events
On April 14, 2015, Coherus BioSciences, Inc. obtained positive results of a repeat Phase 1 pharmacokinetic bioequivalence study for CHS-0214, its etanercept biosimilar candidate. This study was initiated due to the change in the manufacturing location from the United States to the European Union of its CHS-0214 biosimilar candidate, and compared th
4/17/15 - FDA approves first generic Copaxone to treat multiple sclerosis
Sandoz has received FDA approval to market generic glatiramer acetate in a 20 mg/1 ml daily injection. 'Health care professionals and patients can be assured that FDA- approved generic drugs have met the same rigorous standards of quality as the brand-name drug,' said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Resear
4/17/15 - FDA approves generic version of top-selling MS drug Copaxone
The generic, called Glatopa, is made by Sandoz, a unit of Swiss drug company Novartis AG, and U.S.-based Momenta Pharmaceuticals. Shares of Teva, which have been trading around all-time highs, fell 3.8 percent on the day. That's when a key patent on Copaxone will expire, although Teva has introduced a newer formulation of the drug to extend its pat
4/17/15 - Fitch: Generic Copaxone Approval Could Prompt Losses At Teva
While competition in the US for Teva's best-selling multiple sclerosis therapy is now likely to come somewhat sooner than our most recent forecasts, there are no changes to Teva's' BBB+' rating. The FDA Friday approved the first directly substitutable generic version of Copaxone 20 mg. Accordingly, Teva could be in a position to seek damages pendin
4/17/15 - Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA Approval for Glatopa(TM) (glatiramer acetate injection) [Construction Machinery Middle East (United Arab E]
-Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will conduct a conference call to discuss the approval of Glatopa? 20 mg/mL, the first substitutable generic for COPAXONE . Momenta Pharmaceuticals is a biotechnology company specializing in the.
4/17/15 - Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for... [Tripoli Post, The (Libya)]
-Momenta Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted marketing approval of Sandoz's Abbreviated New Drug Application for once daily Glatopa? 20 mg/mL, a generic equivalent of daily COPAXONE 20 mg. Glatopa was developed under a collaboration agreement between Momenta and Sandoz and is the second
4/17/15 - Momenta Spikes Up Following FDA News On Copaxone; StemCells Completes Enrollment of First Cohort in Phase II Pathway Study
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 16, 2015.{ nfg} Teva Pharmaceutical Industries Ltd fell nearly 4 percent Thursday to $63.34 following news that the FDA denied its petition to block generic versions of its Copaxone drug. Mylan NV surged amid the news to $67.76, up 1.48 percent,
4/17/15 - Mylan says it doubts a sale to Teva would get regulatory approval; hasn't received offer
NEW YORK Generic drugmaker Mylan, citing media speculation that Teva Pharmaceutical may be eyeing it as a takeover target, says it doubts that regulators would approve such a deal. Mylan says it is committed to its current strategy as a stand-alone company.
4/17/15 - Mylan Scores Final Win In Patent Challenge On Inhalation Drug
Mylan, which last week unveiled an unsolicited $30 billion offer to acquire Perrigo Company, traded recently at $67, up $0.21 cents. Teva had fallen sharply on Thursday after Novartis AG obtained regulatory approval for a generic version of Teva' s copaxone multiple sclerosis treatment. Teva had appealed a federal court ruling of March 2014 upholdi
4/17/15 - Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries
This independent study, funded by the author, represents the perspectives from 130 patient groups with an interest in diabetes on the corporate reputation of 14 individual pharma companies in 2014. The results from the respondent diabetes patient groups are compared in this report with those from the entire body of 1,150 patient groups covering all
4/17/15 - Shlomo Yanai Joins Sagent Pharmaceuticals Board of Directors [Kuwait News Agency]
-Sagent Pharmaceuticals, Inc., a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that Shlomo Yanai has been appointed to its Board of Directors effective April 15, 2015. Mr. Yanai, 63, served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 until 2012. U
4/17/15 - SSH Shines, First Generic MS Drug Approved, MNOV On Fast Track, ALDX On Watch
LONDON- Aldeyra Therapeutics Inc. has enrolled the first patient in its phase II clinical trial of NS2 for the treatment of noninfectious anterior uveitis. Adamis Pharmaceuticals Corp.' s efficacy trial that was conducted outside of the United States for APC-2000, a generic HFA bronchodilator, has met the primary endpoint. Shares of MediciNova Inc.
4/17/15 - Teva dips as generic Copaxone approved [Globes, Tel Aviv, Israel]
April 17 Teva Pharmaceutical Industries Ltd. has seen its share price drop sharply on Wall Street after it was announced that the US Food and Drug Administration had approved for sale the first generic version of Teva's blockbuster multiple sclerosis treatment Copaxone. In the past four quarters, Teva's revenue from was $4.2 billion, about 21% of
4/17/15 - TWi Pharmaceuticals USA Announces the Receipt of State Sales Licenses from All 50 States in the U.S.
TWi Pharmaceuticals, Inc. today announced that its fully-owned subsidiary, TWi Pharmaceuticals USA, has obtained state sales licenses from all 50 states in the United States. TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ra
4/17/15 - Vanda Reports Trial Date for Fanapt Patent Cases [Health & Beauty Close - Up]
Vanda Pharmaceuticals reported a February 29, 2016 trial date for two pending cases against Roxane Laboratories regarding Roxane's submission of an Abbreviated New Drug Application to obtain approval to make and sell generic Fanapt. No. 13-1973, have been consolidated by agreement of the parties and are scheduled to be tried together in a four-day
4/17/15 - With Biosimilar Drug Development on the Rise, Researchers Explore Efficacy [National News Agency (Lebanon)]
Only a few biosimilars are approved by the EMA, and just one has been approved by the FDA. The article focuses on the first biosimilar monoclonal antibody to be approved in Europe, and appears in the current edition of Immunotherapy, an online, peer-reviewed title from the Future Medicine imprint of Future Science Group. While there is growing i
4/16/15 - Actavis to Host First Quarter 2015 Earnings Conference Call and Webcast
To access the webcast, go to Actavis' Investor Relations Web site at Actavis plc, headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model Growth Pharma. Actavis markets a portfolio of best-in-class products that provide valuable treatments for the central nervous sy
Articles(s): 1 - 25 of 90     Next >>     Go To Page:

© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement